In Brief Gu et al. show that resident microglial proliferation is the major contributor to microgliosis in the spinal dorsal horn after peripheral nerve injury. However, there is no monocyte infiltration associated with injury-induced microgliosis in the dorsal horn. Pharmacological or genetic inhibition of microglial proliferation attenuates neuropathic pain hypersensitivity.
SUMMARY
Peripheral nerve injury causes neuropathic pain accompanied by remarkable microgliosis in the spinal cord dorsal horn. However, it is still debated whether infiltrated monocytes contribute to injuryinduced expansion of the microglial population. Here, we found that spinal microgliosis predominantly results from local proliferation of resident microglia but not from infiltrating monocytes after spinal nerve transection (SNT) by using two genetic mouse models (CCR2 RFP/+ :CX3CR1 GFP/+ and CX3CR1 creER/+ :R26 tdTomato/+ mice) as well as specific staining of microglia and macrophages. Pharmacological inhibition of SNT-induced microglial proliferation correlated with attenuated neuropathic pain hypersensitivities. Microglial proliferation is partially controlled by purinergic and fractalkine signaling, as CX3CR1
À/À and P2Y12 À/À mice show reduced spinal microglial proliferation and neuropathic pain. These results suggest that local microglial proliferation is the sole source of spinal microgliosis, which represents a potential therapeutic target for neuropathic pain management.
INTRODUCTION
Microglia are the principal immune cells in the CNS and play critical roles in the surveillance, support, protection, and restoration of tissue integrity (Kettenmann et al., 2011; Ransohoff and Perry, 2009) . Neuropathic pain resulting from peripheral nerve injury is associated with dramatic microgliosis in the spinal dorsal horn (Calvo and Bennett, 2012; Zhuo et al., 2011) . However, the precise origin of this injury-induced expansion of the microglial population is still debated. Particularly, it is controversial whether blood-derived myeloid progenitors can contribute to the resident microglial pool under neuropathic pain conditions. For instance, several studies using bone marrow chimeras with lethally irradiated recipients favor the view that bone-marrow monocytes are able to cross the blood-brain barrier (BBB) and differentiate into parenchymal microglia (Djukic et al., 2006; Priller et al., 2001) , which is also reported after peripheral nerve injury (Echeverry et al., 2011; Sawada et al., 2014; Zhang et al., 2007) . In contrast, recent studies found that circulating cells do not infiltrate into the parenchyma without irradiation and transplantation (Ajami et al., 2007; Li et al., 2013) , raising the possibility that circulating cells may not cross the intact BBB under pathological conditions.
Given the critical role of microgliosis in neuropathic pain (Salter and Beggs, 2014; Tsuda et al., 2005) , we re-evaluated the infiltration of bone-marrow-derived monocytes in the spinal cord after spinal nerve transection (SNT). We addressed the question using two transgenic mouse lines: (1) double-transgenic CCR2 RFP/+ :CX3CR1 GFP/+ mice in which resident CX3CR1-positive microglia are labeled with GFP while circulating CCR2-positive monocytes are labeled with RFP (Saederup et al., 2010) , and (2) CX3CR1 creER : R26 tdTomato reporter mice, which enabled us to exclusively label resident microglia with tdTomato in the CNS (Parkhurst et al., 2013) . Surprisingly, we found that SNT-induced spinal microgliosis results predominantly from local proliferation of microglia and not from infiltrated monocytes. Pharmacological or genetic inhibition of SNT-induced microglial proliferation attenuated neuropathic pain hypersensitivities. These results provide important insights into the cellular source of microgliosis after peripheral nerve injury and may inform potential therapeutic strategies for the treatment of neuropathic pain. ( Figure S1D ). Since previous studies found blood-derived monocytes in the spinal dorsal horn after partial sciatic nerve injury (Sawada et al., 2014; Zhang et al., 2007) Figures 1A, 1C , and S1G-S1I), probably due to direct injuries of ventral horn motor neurons. CCR2 RFP/+ monocytes were also found in the ipsilateral DRG as well as in the damaged nerve stump ( Figures 1D, 1E , S1D, and S1E). Taking an alternative complementary approach to investigate CCR2 monocyte infiltration in the spinal cord, we monitored CCR2 mRNA by qRT-PCR in sham mice and at POD 7 following SNT. We found that mRNA transcript for CCR2 increased significantly to 5.57 ± 1.03-fold (p = 0.02) in the ipsilateral ventral horn at POD 7 (n = 5) from 1.19 ± 0.32-fold in sham mice (n = 4) or 1.58 ± 0.61-fold in the ipsilateral dorsal horn (n = 5) ( Figure S1J ). Therefore, these results confirm that CCR2-expressing cells are increased in the ipsilateral ventral, but not dorsal, horn at POD 7 after SNT. Finally, to determine whether CCR2 RFP/+ monocytes have the ability to enter the spinal dorsal horn, we used a well-established mouse contusion model of spinal cord injury (SCI) (Wang et al., 2015) in CCR2 (Parkhurst et al., 2013) . This is because resident microglia show a much slower turnover while bloodderived CX3CR1 + cells are quickly replenished (Parkhurst et al., 2013) . We applied tamoxifen (intraperitoneally [i.p.] 150 mg/kg in corn oil, four doses with 2-day intervals) to CX3CR1 creER/+ : R26 tdTomato/+ mice and allowed a 4-week interval for peripheral turnover before SNT surgery ( Figure S3A ). As expected, while CD11b + CX3CR1 + monocytes were largely tdTomato negative ( Figures S3B and S3C Figures 1F, 1G , and S3E-S3G), although these cells were present in the ipsilateral DRG as well as in the damaged nerve stump and ipsilateral ventral horn (data not shown). In addition, Iba1 + tdTomato À monocytes were found in the spinal cord at 7 days after SCI ( Figure S2B ). These results indicate that there is no infiltration of hematogenous CX3CR1 + monocytes in the spinal dorsal horn after SNT.
RESULTS

No
No Monocyte Infiltration after SNT Revealed by P2Y12 and CD169 Immunostaining
To circumvent genetic manipulations, we first used wild-type (WT) mice with immunostaining of P2Y12, a purinergic receptor specific for resident microglia, but not for monocytes or macrophages (Butovsky et al., 2014) , together with immunostaining of Iba1, which labels both resident microglia and infiltrated monocytes. In sham control WT mice, we found all Iba1 + cells had positive P2Y12 staining in the spinal cord ( Figure 2A Figure 2B ). We also did not observe any P2Y12 + cells in the damaged nerve stump at POD 7 after SNT in CX3CR1 GFP/+ mice consistent with microglial specific expression of P2Y12 (Figure 2C) . Next, we studied monocyte infiltration after SNT by performing immunohistochemistry for CD169, a well-known marker for macrophages (Gao et al., 2015) in WT mice. We found that while the sham control spinal cord lacked CD169 + cells, the ipsilateral ventral horn exhibited CD169 + cells whereas the ipsilateral dorsal horn showed no such infiltration at POD 7 after SNT (Figure 2D) . As a positive control, we confirmed the presence of CD169 + macrophages in the L4 DRG at POD 7 after SNT (Figure 2E) . Taken together, by using mice with CCR2 RFP -labeled monocytes, resident microglial tdTomato reporter, microgliaspecific cell marker (P2Y12), and macrophage-specific marker : R26 tdTomato/+ reporter mice are shown in Figure S3 .
(CD169), we have demonstrated that there is no infiltration of peripheral hematogenous monocytes into the spinal cord dorsal horn after peripheral nerve injury. These results collectively indicate that spinal microgliosis after SNT is not due to the monocyte infiltration, in contrast to previous studies (Echeverry et al., 2011; Sawada et al., 2014; Zhang et al., 2007) . (C) No P2Y12 + cells were found in the damaged nerve stump in CX3CR1 GFP/+ mice, and no P2Y12 immunostaining was found in the spinal dorsal horn of P2Y12 À/À mice at POD 7 after SNT (n = 4 per group). Scale bar, 50 mm.
(D) Representative confocal images of double immunostaining showing co-localization of CD169 (green) and Iba1 (red) signals in the ipsilateral spinal cord at POD 7 in WT mice (n = 2-3 mice per group). Scale bar, 100 mm. Note the obvious appearance of CD169 + cells (green) in the ipsilateral VH, but not DH.
(E) CD169 + cell infiltration was also found in L4 dorsal root ganglia (DRG) at POD 7 in WT mice (n = 2-3 mice per group). Scale bar, 50 mm.
Local Proliferation of Resident Microglia Dominates Spinal Microgliosis after SNT
Next, we examined the contribution of microglial proliferation to SNT-induced spinal microgliosis. To this end, we first measured the incorporation of thymidine analog bromodeoxyuridine (BrdU; i.p. 100 mg/kg, two pulses per day for 3 or 7 days) in Iba1 + microglia in spinal dorsal horn after SNT. We found the number of BrdU + Iba1 + microglia (includes actively proliferating and recently post-mitotic cells) in ipsilateral dorsal horn at POD 3 and 7 after SNT was dramatically increased compared to that on the contralateral side or sham control mice ( Figures 3A, 3B , and S4A-S4C). The percentage of BrdU + Iba1 + cells (mitotic microglia) of the total Iba1 + microglial cell population consistently reached up to $90% after SNT (88.8% ± 1.1% at POD 3 and 89.4% ± 1.2% at POD 7; Figure 3C ). In addition, BrdU + Iba1 + cells dominated the BrdU + mitotic cell population (86.1% ± 2.8% at POD 3 and 84.6% ± 1.4% at POD 7; Figure 3D) Figure S4F ). These results indicate that microglial proliferation accounted for most of the proliferating events after SNT. Therefore, local microglial proliferation provides a sustainable source for microgliosis after peripheral nerve injury.
The Dynamics of Microglial Proliferation after SNT To study the dynamics of spinal microglia proliferation, we performed immunostaining for Ki-67 (a nuclear protein expressed in all phases of the cell cycle except the resting phase; Taupin, 2007) to gain a snapshot of dividing microglia at different time points after SNT. We found a marked increase in Ki-67
croglia that started at POD 2, peaked at POD 3, and then returned to pre-injury levels later at POD 5-7 after SNT ( Figures  4A and 4B) . Specifically, the majority of Iba1 + microglial cells are proliferating microglia (Ki-67 + Iba1 + cells) at POD 3 after SNT (89.9% ± 1.4%, Figures S5A and S5B ). To directly monitor local proliferation, we performed time-lapse two-photon imaging of microglia in acute spinal cord slices from CX3CR1 GFP/+ mice. Indeed, we found that 10.6% of microglial cells divided within a 3-hr imaging time window at POD 3 after SNT (15 of 141 microglia from four mice; Figure 4C ; Movie S1). Together, these results provide direct evidence that resident microglia in the dorsal horn undergo active cell division after peripheral nerve injury.
Pharmacological Inhibition of Microgliosis Attenuated Neuropathic Pain Hypersensitivities
If microglial proliferation is the major driver for microgliosis, which is associated with neuropathic pain hypersensitivity, we hypothesized that inhibition of microglial proliferation would attenuate pain after peripheral nerve injury. To test this hypothesis, we intrathecally administrated the anti-mitotic drug cytosine arabinoside (AraC; 50 mg in 5 ml ACSF, twice per day at PODs 1-4 and then once per day at PODs 5-7) immediately after SNT. We found that the number of Iba1 + microglia in the spinal dorsal horn at POD 7 after SNT was significantly reduced (by 39.7%) in AraCtreated mice compared with vehicle-treated mice (p < 0.001; Figures 5A and 5B). Consistently, AraC treatment almost abolished all increased BrdU + Iba1 + cells at POD 7 after SNT in ipsilateral dorsal horn ( Figures S5C and S5F) . Also, there were very few GFAP + cells or NG2 + cells that were co-localized with BrdU labeling ( Figures S5D-S5F ). We found that AraC treatment did not affect GFAP (137 ± 9.9 cells without and 134 ± 8.7 cells with AraC per field of view; n = 5-7; p = 0.83) or NG2 (37.5 ± 2.1 cells without and 34.8 ± 3.6 cells with AraC per field of view; n = 5-6; p = 0.58) cell numbers. Behaviorally, AraC treatment dramatically reduced the SNT-induced thermal hyperalgesia (F (7, 192) = 14.8; day 3-4, p < 0.01; day 5-7, p < 0.001) and mechanical allodynia (F (7, 192) = 45.3; day 2, p < 0.01; day 3-7, p < 0.001; Figure 5C ). In addition, we observed a positive correlation between the number of dorsal horn microglia and the (C) Time-lapse images (180 min) of a dividing GFP + microglia in acute spinal cord slices at POD 3 following SNT. Arrows denote the dividing microglia [parent cells (white arrows); daughter cells (red arrows)] and time is presented as hr:min (n = 4 mice). The dotted box shows the region with magnification. Scale bar represents 100 mm or 10 mm for lower-and higher-magnification images, respectively. Two-photon live imaging of microglia proliferation in the DH from spinal slice at POD3 after SNT is presented in Movie S1.
Figure 5. Microglial Proliferation Determines Neuropathic Pain Hypersensitivities after Spinal Nerve Transection
The anti-mitotic drug cytosine arabinoside (AraC; i.t., 50 mg in 5 ml ACSF, twice per day at PODs 1-4 and then once per day at PODs 5-7) effectively decreases the number of Iba1 + microglia after SNT. extent of allodynia after AraC administration (R = 0.92; Figure 5D ). Therefore, spinal microgliosis due to proliferation directly determines neuropathic pain hypersensitivities after peripheral nerve injury.
Purinergic and Fractalkine Signaling in SNT-Induced Microglial Proliferation
To further investigate the molecular regulators of microglial proliferation after peripheral nerve injury, we turned to the microgliaspecific receptors CX3CR1 and P2Y12 (Butovsky et al., 2014; Cardona et al., 2006) . Consistent with previous reports (Gu et al., 2016; Staniland et al., 2010; Tozaki-Saitoh et al., 2008) , neuropathic pain hypersensitivities were attenuated in both CX3CR1 À/À (F (4, 100) = 44.6; day 2, p < 0.01; day 3, p < 0.001; day 5, p < 0.05; day 7, p < 0.05) and P2Y12 À/À (F (4, 100) = 30.7; day 3, p < 0.001; day 5, p < 0.001; day 7, p < 0.01) mice compared with WT mice after SNT ( Figures S6A  and S6B ). We then examined SNT-induced microglial proliferation by BrdU labeling in CX3CR1 À/À and P2Y12 À/À mice. Interestingly, we found a significant reduction in BrdU + Iba1 + proliferating microglia in the ipsilateral spinal dorsal horn in both CX3CR1
À/À and P2Y12 À/À mice compared with WT mice at POD7 after SNT (BrdU; i.p., once per day at POD1-3; p < 0.05; Figures 5E and 5F ). Detailed analysis showed a decrease in BrdU + Iba1 + cells starting at POD3 in P2Y12 À/À mice compared with those in WT mice after SNT ( Figures S6C-S6E ). These results suggest that both CX3CR1 and P2Y12 receptors participate in microglial proliferation and thereby contribute, at least in part, to neuropathic pain hypersensitivities after peripheral nerve injury.
DISCUSSION
In the present study, we investigated the cellular origin of spinal microgliosis and its contribution to pain hypersensitivities after peripheral nerve injury. Our results show that SNT-induced spinal microgliosis results predominantly from local self-renewal of microglia, but not from infiltrating monocytes. Pharmacological or genetic inhibition of SNT-induced microglial proliferation attenuated neuropathic pain hypersensitivities. The current study provides important insights on the pathogenesis of neuropathic pain in several folds: (1) we unexpectedly found that monocytes do not infiltrate the spinal cord dorsal horn after peripheral nerve injury, in contrast to previous studies (Echeverry et al., 2011; Sawada et al., 2014; Zhang et al., 2007) ; (2) we pinpointed that self-renewal of resident microglia is the cellular basis for SNT-induced spinal microgliosis; (3) we characterized the dynamics of microglial proliferation and directly provided visual evidence of dividing spinal microglia after peripheral nerve injury; and (4) we found that microglial proliferation contributes to the SNT-induced neuropathic pain and is controlled partially by microglial-specific receptors CX3CR1 and P2Y12. Spinal microgliosis is a characteristic of microglial activation following peripheral nerve injury (Calvo and Bennett, 2012; Tsuda et al., 2005; Zhuo et al., 2011) . It was long believed that after peripheral nerve injury, bone-marrow-derived monocytes infiltrate the spinal cord dorsal horn and differentiate into parenchymal microglia (Echeverry et al., 2011; Sawada et al., 2014; Zhang et al., 2007) . Here, based on several lines of evidence through multiple approaches using transgenic CCR2 RFP/+ :CX3CR1 GFP/+ mice, CX3CR1 creER : R26 RFP reporter mice, and P2Y12 and CD169 immunostaining, we found, surprisingly, that there are no monocytes entering the spinal dorsal horn within 14 days of SNT injury. Using bone marrow chimeras with lethal irradiation, previous studies have observed that more than 40% of microglial cells in the spinal dorsal horn after peripheral nerve injury are derived from bone marrow monocytes (Echeverry et al., 2011; Sawada et al., 2014; Zhang et al., 2007) . The discrepancy between these studies and ours is not entirely clear but might be due to the different approaches that were used. It has been proposed that irradiation or bone marrow transplantation may change the overall immune environment and/or impair the blood-brain/spinal barrier, which represents an experimental artifact that cannot be generalized (Ransohoff and Perry, 2009) . In favor of this idea, recent studies showed strong hematopoietic cell engrafts in the mice brain in bone marrow chimeras with lethal irradiation, while no infiltration of hematopoietic cells was observed in the bone marrow chimeras with parabiosis (Ajami et al., 2007) . These studies raised the possibility that circulating cells may not cross the intact blood-brain/spinal barrier without irradiation and/or transplantation, which is consistent with our current study. Interestingly, previous studies found that peripheral nerve injury increased the permeability of the blood/spinal cord barrier (Beggs et al., 2010; Echeverry et al., 2011) , although we did not observe Evans blue staining in spinal cord at POD 7 after SNT (data not shown). Nevertheless, our study suggests that monocytes are not able to infiltrate the spinal dorsal horn even if there is increased permeability of the blood/spinal cord barrier after SNT.
Our study further showed that SNT-induced microgliosis is driven primarily through local proliferation of resident microglia in the spinal dorsal horn. The correlation of nerve injury and microgliosis makes it plausible to assume that primary afferent derived injury signals might be the major trigger for microglial proliferation. Indeed, recent studies suggest neuregulin-1 or colony-stimulating factor 1 (CSF1) are critical for microglial proliferation after peripheral nerve injury (Calvo et al., 2010; Guan et al., 2016) . Here, we found that two microglia-specific receptors, CX3CR1 and P2Y12, participate in the nerve-injuryinduced microglial proliferation in the spinal dorsal horn. Our results may explain at least in part the decreased neuropathic pain hypersensitivities in the current study and those in previous studies (Gu et al., 2016; Staniland et al., 2010; Tozaki-Saitoh et al., 2008; Zhuang et al., 2007) . Although the precise mechanisms underlying CX3CR1 and P2Y12 in chronic pain are still unclear, studies indeed suggest that both receptors are coupled to p38 expression, which could lead to increased inflammatory responses (Kobayashi et al., 2008; Zhuang et al., 2007) . Future studies are needed to address how CX3CR1 and P2Y12 receptors directly or indirectly regulate microglial proliferation in response to peripheral nerve injury. The current study not only furthers our understanding of microglial mechanisms underlying chronic pain but also provides potential therapeutic strategies targeting microgliosis for the treatment of neuropathic pain. (Parkhurst et al., 2013) . Hence, to observe monocyte infiltration, spinal nerve transection or spinal cord contusion injury was performed at 4 weeks after TM inductions.
Spinal Nerve Transection Surgery
Mice were anesthetized with isoflurane in O 2 (induction: 4%-5% isoflurane; maintenance: 1.5%-2.5% isoflurane). Lumbar 4 SNT surgery was performed as previously described (Chung et al., 2004; Gu et al., 2016) . Briefly, a small incision to the skin overlaying L4-S1 was made, followed by retraction of the paravertebral musculature from the vertebral transverse processes. The L4 spinal nerve was identified, lifted slightly, transected, and removed 1-1.5 mm from the end to DRG. The wound was irrigated with saline and closed in with a two-layer suture by closing the muscles with 6-0 silk sutures and the skin with 5-0 silk sutures. The L4 spinal nerve was exposed without ligation or transection in sham-operated mice. POD was used to represent the time point following SNT.
Drug Administration
The thymidine analog BrdU (Sigma) was used to label proliferating and recently postmitotic cells in the spinal cord after SNT surgery. The BrdU solution was diluted in 1 M PBS just before use and intraperitoneally administered (i.p. 100 mg/kg). To inhibit microglial proliferation, the anti-mitotic drug AraC (50 mg in 5 ml ACSF) was intrathecally injected to mice at given time points after SNT. For intrathecal (i.t.) drug administration, mice were hand restricted and injected by direct lumbar puncture between L5 and L6 vertebrae of the spine, using a 10-ml Hamilton syringe (Hamilton Bonaduz AG) with a 31G needle. Successful insertion was indicated by a tail flick response. 
